The Effects of Levosimendan Exposure on Oxidant/Antioxidant Status and Trace Element Levels in the Pulmonary Artery of Rats by Yasin Ay et al.
The Effects of Levosimendan Exposure on Oxidant/Antioxidant
Status and Trace Element Levels in the Pulmonary Artery of Rats
Yasin Ay • Cemalettin Aydın • Halil Basel •
Hava Bektas¸ • Gu¨lay Bu¨lu¨t • Bekir I˙nan •
Nuray Kahraman Ay • I˙smail Demir
Received: 19 February 2013 / Accepted: 3 May 2013 / Published online: 15 May 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract We investigated both the effect of levosimendan
and the role of oxidant/antioxidant status and trace element
levels in the pulmonary artery of rats. Fourteen male Wistar
albino rats were randomly divided into two groups of seven
animals each. Group 1 was not exposed to levosimendan and
served as a control. Levosimendan (12 lg/kg) diluted in
10 ml 0.9 % NaCl was administered intraperitoneally to
group 2. Animals of both groups were killed after 3 days,
and their pulmonary arteries were harvested to determine
changes in tissue oxidant/antioxidant status and trace ele-
ment levels. The animals in both groups were killed 72 h
after the levosimendan exposure treatment, and pulmonary
arteries were harvested to determine levels of the lipid
peroxidation product MDA and the antioxidant GSH as well
as the decreased activity of antioxidant enzymes such as
SOD, GSH-Px and CAT. It was found that MDA levels
increased in pulmonary artery tissues of rats after levosim-
endan administration. The GSH level decreased in the pul-
monary artery of rats after levosimendan treatment. Co, Mn,
Fe, Cd and Pb levels were significantly higher (P \ 0.001)
and Mg, Zn and Cu levels significantly lower (P \ 0.001) in
the levosimendan group compared to the control group.
These results suggest that levosimendan treatment caused an
increase in free radical production and a decrease in anti-
oxidant enzyme activity in the pulmonary artery of levo-
simendan-treated rats. It also caused a decrease or increase
in the levels of many minerals in the pulmonary artery,
which is an undesirable condition for normal pharmaco-
logical function.
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Introduction
Levosimendan causes venous, arterial and coronary vaso-
dilation, probably by opening ATP-sensitive potassium
channels in smooth muscle. Dose-dependent hypotension
may occur. Levosimendan is also of benefit in the setting of
pulmonary vasoconstriction and right ventricular dysfunc-
tion and reduces pulmonary vascular resistance (Kamath
et al. 2009). Congestive heart failure is a complex hemo-
dynamic and metabolic syndrome in which both cardiac
function and metabolism are impaired (Cohen-Solal et al.
1995). An important characteristic of this condition is an
imbalance between energy production and utilization.
Oxygen consumption in the heart is correlated with cardiac
workload (Balaban 1990). Dilated cardiomyopathy refers
to a weakened cardiac muscle that is unable to pump
strongly enough to empty the heart properly in each beat.
In restrictive cardiomyopathy, the muscle becomes so
stiffened and inextensible that the heart cannot fill properly
between beats. The degeneration of myocardium associated
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with muscular dystrophy is often accompanied by cardio-
myopathy (Colledge et al. 2010; Basel et al. 2012). Lev-
osimendan is a cardiovascular drug for the treatment of
acute and decompensated heart failure. It has positive
inotropic and antistunning effects mediated by calcium
sensitization of contractile proteins (Pollesello and Papp
2007; Jamali et al. 1997) and vasodilatory and anti-ische-
mic effects mediated by the opening of ATP-sensitive
potassium (KATP) channels in vascular smooth muscle
cells (Jamali et al. 1997; De Witt et al. 2002). Levosim-
endan has a vasodilatory effect via opening of KATP
channels in the plasma membrane of vascular smooth
muscle cells, activates myocardial mitochondrial KATP
(m-KATP) channels and exerts a PreC effect against
ischemia–reperfusion injury (Kersten et al. 2000).
The family of reactive oxygen species (ROS) includes
highly bioactive, short-living molecules that are derived
from reduction of molecular oxygen. Multiple enzyme
systems use different substrates as sources of electrons to
produce a variety of ROS, including superoxide, hydroxyl
radical, hydrogen peroxide, peroxynitrite, hypochlorous
acid and lipid radicals. Several enzymes are expressed in
vascular tissue that contribute to the production as well as
to the degradation of ROS. Under physiological conditions,
ROS formation and elimination are delicately balanced in
the vascular wall. However, enhanced activity of oxidant
enzymes and/or reduced activity of antioxidant enzymes
lead to oxidative stress (Wassmann et al. 2004). The
superoxide dismutases (SODs) are a major cellular defense
system against superoxide in all vascular cells. These
enzymes contain redox metals in the catalytic center and
dismutase superoxide radicals to hydrogen peroxide and
oxygen (Wassmann et al. 2004). Reduced glutathione
(GSH) plays a major role in the regulation of the intra-
cellular redox state of vascular cells by providing reducing
equivalents for many biochemical pathways. Glutathione
peroxidase (GPx) is a selenium-containing antioxidant
enzyme that effectively reduces hydrogen peroxide and
lipid peroxides to water and lipid alcohols, respectively,
and in turn oxidizes glutathione to glutathione disulfide.
Malondialdehyde (MDA) is an indicator of lipid peroxi-
dation and increases in various diseases (Nordberg and
Arner 2001). Catalase (CAT) is mainly a heme-containing
enzyme. The predominant subcellular localization of
enzyme is peroxisomes, in which it catalyzes the dismu-
tation of hydrogen peroxide to water and molecular oxy-
gen. CAT activity is highest in the liver, relatively high in
kidney and very low in heart (Nordberg and Arner 2001).
Trace elements are being increasingly recognized as
essential mediators for the development and progression of
heart diseases. It is well known that selenium (Se), zinc (Zn)
and copper (Cu) in serum can affect certain heart diseases
such as Keshan disease heart failure, cardiomyopathy and
atherosclerosis. Therefore, trace elements may play an
important role in the etiopathogenesis of the diseases (Kosar
et al. 2006). Trace elements may also play an important
role in alleviating tissue damage due to formation of free
radicals.
Hence, a systemic approach has been used in the present
study to focus on cardiovascular disease. Oxidative stress
was measured by the serum levels of MDA, enzymic GPx
and SOD as well as trace element levels in the pulmonary
artery. With the assumption that levosimendan directed to
the pulmonary artery also affects adjacent organs in rats,
we designed our study to investigate the effect of levo-
simendan exposure of the pulmonary artery on oxidative




Fourteen male Wistar albino rats, approximately 6 months
of age, with an average body weight of 250–300 g were
obtained from the Animal Laboratory of Bezmialem Vakif
University (Istanbul, Turkey). Rats were housed in specific
cages (18 rats/5 rats). A 12-h light/dark cycle was main-
tained, and the rats were fed ad libitum.
The animals were randomly divided into two groups,
each consisting of seven rats. The animals in group 1 were
not treated with drug and served as a control. Levosim-
endan (12 lg/kg) diluted in 10 ml 0.9 % NaCl was
administered intraperitoneally. After 3 days, animals in
both groups were killed and their pulmonary arteries har-
vested for the evaluation of tissue oxidant/antioxidant sta-
tus and trace element levels after levosimendan exposure.
Biochemical Analysis
Measurement of MDA Level
A 50-mg tissue specimen was homogenized in 0.15 M
KCl. After centrifugation of the homogenate at 1,6009g,
MDA levels in tissue homogenate supernatant were
determined by the thiobarbituric acid (TBA) reaction
according to Yagi (1994). The principle of this method is
based on measuring absorbance of the pink color produced
by the interaction of TBA with MDA at 530 nm.
Measurements of SOD and GSH-Px Enzyme Activities
Tissues were homogenized in physiological saline (1 g in
5 ml) using a homogenizer (B. Braun, Melsungen,
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Germany) and centrifuged at 4,0009g for 20 min (Heraus,
Hanau, Germany). GSH-Px activity was determined by
monitoring the changes in NADPH absorbance at 340 nm
and by measuring the decrease of H2O2 absorbance at
240 nm (Aebi 1974). SOD activity was measured by the
method based on the nitroblue tetrazolium (NBT) reduction
rate. One unit of SOD activity is the amount of enzyme
protein causing 50 % inhibition of the NBT reduction rate
(Durak et al. 1996).
Measurement of GSH Level
GSH levels were measured by the technique of Sedlak and
Lindsay (1968) at 412 nm. Samples were precipitated with
50 % trichloroethanoic acid and centrifuged at 1,0009g for
5 min. The reaction mixture contained 0.5 ml of superna-
tant, 2.0 ml of Tris-EDTA buffer (0.2 M, pH 8.9) and
0.1 ml of 10 mM dithiobis(2-nitrobenzoic acid) (DTNB).
The solution was kept at room temperature for 5 min, and
subsequently absorbance was read at 412 nm.
Measurement of CAT Enzyme Activity
Erythrocyte CAT activity was measured by the method
described by Aebi (1974). Briefly, the supernatant (0.1 ml)
was added to a quartz cuvette containing 2.95 ml of
19 mM H2O2 prepared in potassium phosphate buffer
(50 mM, pH 7.00). The change in absorbance was moni-
tored at 240 nm for 5 min using a spectrophotometer (UV-
1201; Shimadzu, Kyoto, Japan).
Measurement of Carbonic Anhydrase Activity
Carbonic anhydrase (CA) activity was assayed by hydra-
tion of CO2 measured by the method of Rickli and Wilbur-
Anderson (Topcuoglu et al. 2009) using bromothymol blue
as indicator.
Measurements of Mineral Levels
Two milliliters of the mixture of HNO3/H2O2 (2:1) was
added to 0.7 g of the tissue sample. The mixture was
placed in a water bath at 70 C for 30 min and stirred
occasionally; subsequently, 1.0 ml of the same acid mix-
ture was added and the suspension was transferred to a
Teflon vessel for digestion in a microwave oven. The bomb
was closed, and radiation was applied for 3 min at 450 W.
After the addition of 0.5 ml of the same acid mixture,
radiation was repeated for 3 min. After cooling for 5 min,
2.0 ml of 0.1 M HNO3 was added, and the solution was
transferred to a Pyrex tube. After centrifugation, clear
solution was used for the determination of Cu, Zn, Mg, Mn,
Pb, Cd and Fe (Bush et al. 1995). Measurements were
performed by atomic absorption spectrophotometry using a
UNICAM-929 spectrophotometer (Unicam, Leeds, UK).
Statistical Analysis
Data are reported as means ± SD. The parameters were
compared between two groups using the Mann–Whitney
U test. All statistical analyses were carried out using the
SPSS statistical software package (SPSS for Windows
version 13.0; SPSS, Inc., Chicago, IL, USA), and P B 0.05
was considered significant.
Results
The lipid peroxidation product MDA level increased sig-
nificantly (P \ 0.001) in the pulmonary artery of rats after
levosimendan treatment (Table 1). The level of the anti-
oxidant GSH decreased in the pulmonary artery of rats
after levosimendan treatment. Co, Mn, Fe, Cd and Pb
levels in the pulmonary artery were significantly higher
(P \ 0.001); and Mg, Zn and Cu were significantly
decreased (P \ 0.001) in the levosimendan group com-
pared to the control group (Table 2).
Discussion
Atherosclerosis is a process for which there is substantial
evidence of a role for oxidative stress. Hypercholesterol-
emia and triglyceridemia are independent risk factors that
alone or together can accelerate the development of coro-
nary artery disease and progression of atherosclerotic
lesions (Kaviarasan et al. 2005). This study was carried out
to investigate the effect of intraperitoneal injection of
levosimendan on oxidative stress of pulmonary artery in
rats. The pharmacokinetics of levosimendan underpins the
prolonged beneficial hemodynamic effects that result from
a single-dose regime. It is an appealing and promising
alternative adjunct to current therapies for cardiac failure.
Levosimendan is also of benefit in the setting of pulmonary
vasoconstriction and right ventricular dysfunction (Kamath
et al. 2009). Levosimendan also has been evaluated as a
bridge therapy for the perioperative phase of cardiac sur-
gery (Pollesello and Papp 2007). Many compounds that
open KATP channels in the cell plasma membrane also
have been shown to act on KATP channels in mitochondria
(Grover and Garlid 2000; Gross 2000). There is a con-
sensus that the opening of m-KATP channels (Gross 2000)
protects the heart against ischemia–reperfusion damage.
The increased potassium influx associated with m-KATP
channel opening is sufficient to protect/preserve mito-
chondrial function, most probably via the normalization of
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matrix and intermembrane space volumes, in situations of
distress such as ischemia and/or reperfusion (Garlid et al.
2003).
In the present study, it was found that lipid peroxidation
products decreased in the pulmonary artery after levosim-
endan treatment in rats. These results suggest that levo-
simendan administration may increase or decrease
oxidative stress by decreasing free radical production in the
pulmonary artery. Oxidative stress may lead to many cel-
lular events, such as inactivation of NO, oxidative modi-
fications of DNA and proteins, lipid oxidation, enhanced
mitogenicity and apoptosis of vascular cells as well as
increased expression and activation of redox-sensitive
genes, such as the receptor for oxidized LDL, adhesion
molecules, chemotaxis factors, proinflammatory cytokines,
regulators of cell cycle progression and matrix metallo-
proteinases. Several cardiovascular risk factors are asso-
ciated with oxidative stress and dysregulated expression
and activity of oxidant and antioxidant enzymes, including
arterial hypertension and hypercholesterolemia; and the
described effects of ROS and impaired NO bioactivity in
vascular cells contribute to the development and progres-
sion of atherosclerosis at all stages of the disease. Increased
levels of ROS were demonstrated in all layers of the dis-
eased arterial wall and within the atherosclerotic plaque.
Many studies have demonstrated upregulation of several
vascular NADPH oxidase subunits and increased enzyme
activity in atherosclerotic animals and humans and after
vascular injury (Sorescu et al. 2002; Spiekermann et al.
2003; Szo¨cs et al. 2002).
The antioxidant defense systems exist to prevent the
formation of these increased reactive and free radicals.
These include SOD, CA and other free radical scavengers,
such as GSH. In our study, GSH levels increased and the
activities of antioxidant enzymes, such as SOD and CA,
decreased in pulmonary artery tissues of levosimendan-
treated rats. The increased formation of ROS and decreased
antioxidant defense are defined as oxidative stress, which is
widely recognized as an important feature of many dis-
eases. The decrease in antioxidant enzyme activities might
be due to their use against free radical destruction or their
inhibition by free radical species (Percy et al. 1990). DNA
and proteins cause a loss of cell integrity, enzyme function
and genomic stability (Paglia and Valentine 1967).
Because glucose-6-phosphate dehydrogenase (G6PD) cat-
alyzes the first step of the pentose phosphate pathway,
Table 1 Effect of levosimendan administration on tissue pulmonary artery levels of MDA, an indicator of oxidative stress, and levels of
enzymes that act in cell defense against oxidative stress
Control Levosimendan
Median Mean SD Median Mean SD P
SOD (U/mg) 18.980 19.046 0.380 8.183 7.946* 0.890 0.001
MDA (mg/dl) 86.051 85.883 0.580 116.785 117.192* 1.388 0.001
GSH-Px (EU/gHb)-1 141.100 141.614 3.268 77.602 77.502* 0.357 0.001
GSH (EU/gHb)-1 104.045 103.734 3.706 77.355 77.417* 0.385 0.001
CA (EU/gHb)-1 0.066 0.067 0.003 0.077 0.070 0.012 0.639
CAT (EU/gHb)-1 62.111 62.419 1.536 41.643 41.714* 2.868 0.001
Data are reported as mean ± SD for n = 8/group. Rats were treated with levosimendan (12 lg/kg day, ip) for 3 days
SOD superoxide dismutase, GSH-Px glutathione peroxidase, CA carbonic anhydrase, CAT catalase, GSH antioxidant glutathione, MDA
malondialdehyde
* P \ 0.001 compared to control
Table 2 Effect of
levosimendan treatment on
pulmonary artery tissue trace
element levels
Data are reported as
mean ± SD for n = 10/group.
Rats were treated with
levosimendan (12 lg/kg day,
ip) for 3 days
* P \ 0.001 compared to
control
Control Levosimendan
Median Mean SD Median Mean SD P
Co (lg/dl) 0.322 0.325 0.014 0.552 0.568* 0.044 0.001
Pb (lg/dl) 0.083 0.072 0.022 0.270 0.280* 0.050 0.001
Cd (lg/dl) 0.014 0.015 0.002 0.076 0.076* 0.004 0.001
Mg (lg/dl) 28.550 28.344 0.616 18.560 18.849* 1.165 0.001
Mn (lg/dl) 0.014 0.013 0.002 0.054 0.054* 0.004 0.001
Fe (lg/dl) 1.460 1.427 0.088 30.470 30.350* 0.406 0.001
Cu (lg/dl) 0.122 0.126 0.022 0.075 0.074* 0.003 0.001
Zn (lg/dl) 4.855 4.787 0.516 3.475 3.255* 0.500 0.001
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which provides the NADPH necessary for conversion of
oxidized glutathione to GSH, the increased tissue GSH
level was probably due to the increased G6PD activity that
caused the increased production of GSH.
A healthy life depends on the existence of appropriate
amounts of various heavy elements. Deficiency in any of
these trace elements leads to undesirable pathological
conditions that can be prevented or reversed by adequate
supplementation (Fraga 2005). We found that levels of Co,
Mn, Fe, Cd and Pb in the pulmonary artery were signifi-
cantly higher (P \ 0.001) and those of Mg, Zn and Cu
were significantly decreases (P \ 0.001) in the levosim-
endan group compared to the control group.
In contrast, trace element deficiency causes cardiomy-
opathy as a result of the depletion of essential enzymes,
which protect the cell membrane from damage by free
radicals due to the trace elements playing a key role in
essential enzymes such as GPx and SOD. It is therefore not
surprising that one of the important biological functions of
trace elements is antioxidation. GPx and SOD reduce the
production of hydrogen peroxide and superoxide, therefore
diminishing the propagation of free radicals (Kosar et al.
2006; Bolli 1988).
These results suggest that short-term levosimendan
treatment caused an increase in free radical production and
a decrease in antioxidant enzyme activity in the pulmonary
artery of levosimendan-treated rats. It also caused a
decrease or increase in the levels of many minerals in the
pulmonary artery, which is an undesirable condition for
normal pharmacological function.
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